Rapport Therapeutics, Inc. (RAPP)
NASDAQ: RAPP · Real-Time Price · USD
22.18
-0.02 (-0.07%)
Nov 21, 2024, 10:31 AM EST - Market open
Rapport Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Net Income | -71.85 | -34.79 | -11.62 |
| Depreciation & Amortization | 0.63 | 0.11 | 0.02 |
| Asset Writedown & Restructuring Costs | - | - | 5.45 |
| Loss (Gain) From Sale of Investments | -3.85 | -0.08 | - |
| Stock-Based Compensation | 8.03 | 3.53 | 0.61 |
| Other Operating Activities | 8.11 | 1.39 | 0.38 |
| Change in Accounts Payable | -0.27 | 0.86 | 1.58 |
| Change in Other Net Operating Assets | -1.54 | 1.8 | 0.05 |
| Operating Cash Flow | -60.74 | -27.18 | -3.54 |
| Capital Expenditures | -3.62 | -1.64 | -0.31 |
| Sale (Purchase) of Intangibles | - | - | -5.45 |
| Investment in Securities | -277.12 | -77.22 | - |
| Investing Cash Flow | -280.73 | -78.86 | -5.76 |
| Total Debt Issued | - | - | 8.73 |
| Net Debt Issued (Repaid) | - | - | 8.73 |
| Issuance of Common Stock | 157.71 | 0.05 | 0.03 |
| Repurchase of Common Stock | - | -0 | - |
| Other Financing Activities | -0.13 | -0.13 | -0.11 |
| Financing Cash Flow | 221.48 | 145.14 | 43.29 |
| Net Cash Flow | -119.99 | 39.1 | 33.99 |
| Free Cash Flow | -64.36 | -28.82 | -3.85 |
| Free Cash Flow Per Share | -5.20 | -19.14 | -4.95 |
| Levered Free Cash Flow | - | -17.43 | - |
| Unlevered Free Cash Flow | - | -17.43 | - |
| Change in Net Working Capital | - | -3.19 | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.